NASDAQ:CNCE

Concert Pharmaceuticals - CNCE Stock Forecast, Price & News

$6.13

-0.02 (-0.33%)

(As of 08/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $5.91
▼
$6.17
50-Day Range: $4.09
▼
$6.36
52-Week Range: $2.57
▼
$6.88

Volume: 1.04 million shs
Average Volume: 462,843 shs
Market Capitalization: $222.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.00

Concert Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 95.8% Upside
$12.00 Price Target
Short Interest: Healthy
3.03% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.93
Upright™ Environmental Score
News Sentiment: 0.57
Based on 18 Articles This Week
Insider Trading: Acquiring Shares
$49,998 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($3.47) to ($2.07) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

171st out of 1,283 stocks

Pharmaceutical Preparations Industry

69th out of 615 stocks

3.5

Analyst's Opinion

Consensus Rating
Concert Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, Concert Pharmaceuticals has a forecasted upside of 95.8% from its current price of $6.13.
Amount of Analyst Coverage
Concert Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.03% of the outstanding shares of Concert Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Concert Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Concert Pharmaceuticals has recently increased by 16.45%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Concert Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Concert Pharmaceuticals does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Concert Pharmaceuticals has received a 69.07% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for physiological diseases " and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Concert Pharmaceuticals is -0.93.

2.5

News and Social Media Coverage

News Sentiment
Concert Pharmaceuticals has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 18 news articles for Concert Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 10 people have searched for CNCE on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Concert Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Concert Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,998.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
11.00% of the stock of Concert Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
51.26% of the stock of Concert Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Concert Pharmaceuticals are expected to grow in the coming year, from ($3.47) to ($2.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Concert Pharmaceuticals is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Concert Pharmaceuticals is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Concert Pharmaceuticals has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Concert Pharmaceuticals (NASDAQ:CNCE) Stock

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Concert Pharmaceuticals in a research note on Wednesday, June 15th. They set a "hold" rating on the stock.

Concert Pharmaceuticals Stock Performance

CNCE opened at $6.13 on Friday. The company's fifty day moving average price is $4.85 and its two-hundred day moving average price is $3.89. Concert Pharmaceuticals has a 1-year low of $2.57 and a 1-year high of $6.88.

Concert Pharmaceuticals (NASDAQ:CNCE - Get Rating) last announced its earnings results on Thursday, May 5th. The biotechnology company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.07). Concert Pharmaceuticals had a negative net margin of 245.72% and a negative return on equity of 125.90%. During the same quarter in the previous year, the company posted ($0.67) earnings per share. Equities analysts forecast that Concert Pharmaceuticals will post -3.47 earnings per share for the current year.

Insider Activity

In related news, Director Heek Christi Van acquired 10,526 shares of the firm's stock in a transaction that occurred on Monday, June 6th. The stock was acquired at an average price of $4.75 per share, for a total transaction of $49,998.50. Following the completion of the acquisition, the director now owns 25,651 shares of the company's stock, valued at approximately $121,842.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.00% of the stock is currently owned by corporate insiders.

Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Stock News Headlines

August 6, 2022 | seekingalpha.com

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2022 Results - Earnings Call Transcript

August 5, 2022 | finance.yahoo.com

What Makes Concert (CNCE) a Good Fit for "Trend Investing"

August 7, 2022 | Investing Daily (Ad)

27 U.S. Cities Where Stocks Yield 26% a Year

What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

August 5, 2022 | americanbankingnews.com

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Short Interest Up 16.5% in July

August 5, 2022 | americanbankingnews.com

Jefferies Financial Group Weighs in on Concert Pharmaceuticals, Inc.'s Q2 2022 Earnings (NASDAQ:CNCE)

August 4, 2022 | msn.com

Recap: Concert Pharma Q2 Earnings

August 4, 2022 | finance.yahoo.com

Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Lags Revenue Estimates

August 4, 2022 | finance.yahoo.com

Does Concert (CNCE) Have the Potential to Rally 158% as Wall Street Analysts Expect?

August 7, 2022 | Investing Daily (Ad)

27 U.S. Cities Where Stocks Yield 26% a Year

August 4, 2022 | finance.yahoo.com

Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results

August 1, 2022 | finance.yahoo.com

Concert Pharma Aces Second Trial For Patchy Hair Loss Hopeful

August 1, 2022 | seekingalpha.com

Concert says second late-stage study for hair loss therapy reached main goal

August 1, 2022 | finance.yahoo.com

Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata

July 29, 2022 | finance.yahoo.com

Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022

July 17, 2022 | americanbankingnews.com

Comparing Concert Pharmaceuticals (NASDAQ:CNCE) & Biotech Acquisition (NASDAQ:BIOT)

July 7, 2022 | finance.yahoo.com

What Is The Ownership Structure Like For Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)?

June 17, 2022 | seekingalpha.com

Concert Pharmaceuticals: A Balanced Risk/Reward

June 14, 2022 | finance.yahoo.com

Trade Alert: The Co-Founder & Independent Chairman of the Board Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE), Richard Aldrich, Has Just Spent US$1m Buying 62% More Shares

June 9, 2022 | finance.yahoo.com

Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference

June 7, 2022 | finance.yahoo.com

Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology

June 6, 2022 | seekingalpha.com

Concert Pharmaceuticals raises $66.4M through share offering and warrant exercise

June 6, 2022 | finance.yahoo.com

Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants

June 5, 2022 | seekingalpha.com

Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug

June 3, 2022 | finance.yahoo.com

Concert Pharmaceuticals (NASDAQ:CNCE) shareholders have endured a 65% loss from investing in the stock five years ago

June 1, 2022 | markets.businessinsider.com

Mid-Afternoon Market Update: Nasdaq Drops 100 Points; Concert Pharmaceuticals Shares Plummet

June 1, 2022 | seekingalpha.com

Concert Pharma slides on 10M common stock offering

May 23, 2022 | finance.yahoo.com

Concert Pharma's CTP-543 Shows Clinical Efficacy Against Scalp Hair Loss

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Company Calendar

Last Earnings: 11/09/2021
Today: 8/07/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CNCE
CUSIP: N/A
CIK: 1367920
Web: www.concertpharma.com
Phone: (781) 860-0045
Fax: 302-636-5454
Employees: 64
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $12.00
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +95.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.41)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-80,050,000.00
Net Margins: -245.72%
Pretax Margin: -291.99%
Return on Equity: -125.90%
Return on Assets: -85.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.61
Quick Ratio: 7.61

Sales & Book Value

Annual Sales: $32.58 million
Price / Sales: 6.84
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.24 per share
Price / Book: 1.89

Miscellaneous

Outstanding Shares: 36,330,000
Free Float: 32,333,000
Market Cap: $222.70 million
Optionable: Optionable
Beta: 0.69

Key Executives

Mr. Richard H. Aldrich M.B.A. (Age 68)
Mba, Co-Founder & Independent Chairman
Comp: $80k
Dr. Roger D. Tung Ph.D. (Age 62)
Co-Founder, CEO, Pres & Exec. Director
Comp: $979.29k
Mr. Marc A. Becker (Age 50)
Chief Financial Officer
Comp: $677.05k
Dr. James V. Cassella Ph.D. (Age 67)
Chief Devel. Officer
Comp: $738.48k
Ms. Nancy Stuart (Age 64)
Chief Operating Officer
Ms. Justine E. Koenigsberg
Sr. VP of Corp. Communications & Investor Relations
Mr. Jeffrey A. Munsie (Age 45)
Chief Legal Officer & Corp. Sec.
Ms. Christine Boisclair
Sr. VP of Regulatory Affairs & Quality Assurance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CNCE Stock - Frequently Asked Questions

Should I buy or sell Concert Pharmaceuticals stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Concert Pharmaceuticals stock.
View analyst ratings for Concert Pharmaceuticals or view top-rated stocks.
What is Concert Pharmaceuticals' stock price forecast for 2022?: 3 Wall Street analysts have issued twelve-month price objectives for Concert Pharmaceuticals' stock. Their CNCE stock forecasts range from $9.00 to $17.00. On average, they predict Concert Pharmaceuticals' stock price to reach $12.00 in the next year. This suggests a possible upside of 95.8% from the stock's current price.
View analysts' price targets for Concert Pharmaceuticals or view top-rated stocks among Wall Street analysts.
How has Concert Pharmaceuticals' stock performed in 2022?: Concert Pharmaceuticals' stock was trading at $3.15 at the beginning of the year. Since then, CNCE shares have increased by 94.6% and is now trading at $6.13.
View the best growth stocks for 2022 here.
Are investors shorting Concert Pharmaceuticals?: Concert Pharmaceuticals saw a increase in short interest in July. As of July 15th, there was short interest totaling 1,100,000 shares, an increase of 16.5% from the June 30th total of 944,600 shares. Based on an average daily volume of 818,800 shares, the short-interest ratio is presently 1.3 days.
View Concert Pharmaceuticals' Short Interest.
When is Concert Pharmaceuticals' next earnings date?: Concert Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our earnings forecast for Concert Pharmaceuticals.
How were Concert Pharmaceuticals' earnings last quarter?: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.81) by $0.03. The biotechnology company had revenue of $0.54 million for the quarter, compared to the consensus estimate of $0.25 million. Concert Pharmaceuticals had a negative net margin of 245.72% and a negative trailing twelve-month return on equity of 125.90%. During the same quarter in the previous year, the firm posted ($0.60) earnings per share.

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?: 1 employees have rated Concert Pharmaceuticals CEO Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among Concert Pharmaceuticals' employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Concert Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Intel (INTC).
What is Concert Pharmaceuticals' stock symbol?: Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."
Who are Concert Pharmaceuticals' major shareholders?: Concert Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.51%), Connor Clark & Lunn Investment Management Ltd. (0.83%) and Black Diamond Financial LLC (0.19%). Company insiders that own Concert Pharmaceuticals stock include Heek Christi Van, James V Cassella, Jeffrey A Munsie, Marc A Becker, Nancy Stuart, Peter Barton Hutt, Roger D Tung and Thomas G Auchincloss.
View institutional ownership trends for Concert Pharmaceuticals.
How do I buy shares of Concert Pharmaceuticals?: Shares of CNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Concert Pharmaceuticals' stock price today?: One share of CNCE stock can currently be purchased for approximately $6.13.
How much money does Concert Pharmaceuticals make?: Concert Pharmaceuticals (NASDAQ:CNCE) has a market capitalization of $222.70 million and generates $32.58 million in revenue each year. The biotechnology company earns $-80,050,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis.
How many employees does Concert Pharmaceuticals have?: Concert Pharmaceuticals employs 64 workers across the globe.
How can I contact Concert Pharmaceuticals?: Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The official website for Concert Pharmaceuticals is www.concertpharma.com. The biotechnology company can be reached via phone at (781) 860-0045, via email at ir@concertpharma.com, or via fax at 302-636-5454.

This page (NASDAQ:CNCE) was last updated on 8/7/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Concert Pharmaceuticals - CNCE Stock Forecast, Price & News

Concert Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Concert Pharmaceuticals (NASDAQ:CNCE) Stock

Analysts Set New Price Targets

Concert Pharmaceuticals Stock Performance

Insider Activity

CNCE Stock News Headlines

CNCE Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CNCE Stock - Frequently Asked Questions

Should I buy or sell Concert Pharmaceuticals stock right now?

What is Concert Pharmaceuticals' stock price forecast for 2022?

How has Concert Pharmaceuticals' stock performed in 2022?

Are investors shorting Concert Pharmaceuticals?

When is Concert Pharmaceuticals' next earnings date?

How were Concert Pharmaceuticals' earnings last quarter?

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?

What other stocks do shareholders of Concert Pharmaceuticals own?

What is Concert Pharmaceuticals' stock symbol?

Who are Concert Pharmaceuticals' major shareholders?

How do I buy shares of Concert Pharmaceuticals?

What is Concert Pharmaceuticals' stock price today?

How much money does Concert Pharmaceuticals make?

How many employees does Concert Pharmaceuticals have?

How can I contact Concert Pharmaceuticals?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™